Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk

Dow Jones

02/13

0820 GMT - Sanofi's abrupt move to replace CEO Paul Hudson with Merck KGaA's head Belen Garijo only adds to near-term uncertainty for the French drugmaker, Citi analysts say in a research note. The company suffered several setbacks in clinical trials in the past year and needs to focus on a research-and-development turnaround, the analysts say. Garijo brings a long pharma career to the role, but a candidate from a major drugmaker with strong credentials in research-and-development and business development would have made a more immediate impact, according to Citi. "We therefore feel that it may take time for the appointment to have an impact on the shares as we wait to see what actions the new CEO will take." Shares are down 0.6% at 78.59 euros. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

February 13, 2026 03:21 ET (08:21 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2611422131"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611422131\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611422131?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 16:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611422131","market":"fut","top_or_hot":-1,"title":"Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0820 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s abrupt move to replace CEO Paul Hudson with <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a>'s head Belen Garijo only adds to near-term uncertainty for the French drugmaker, Citi analysts say in a research note. The company suffered several setbacks in clinical trials in the past year and needs to focus on a research-and-development turnaround, the analysts say. Garijo brings a long pharma career to the role, but a candidate from a major drugmaker with strong credentials in research-and-development and business development would have made a more immediate impact, according to Citi. \"We therefore feel that it may take time for the appointment to have an impact on the shares as we wait to see what actions the new CEO will take.\" Shares are down 0.6% at 78.59 euros. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 13, 2026 03:21 ET (08:21 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-13 16:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0820 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s abrupt move to replace CEO Paul Hudson with <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a>'s head Belen Garijo only adds to near-term uncertainty for the French drugmaker, Citi analysts say in a research note. The company suffered several setbacks in clinical trials in the past year and needs to focus on a research-and-development turnaround, the analysts say. Garijo brings a long pharma career to the role, but a candidate from a major drugmaker with strong credentials in research-and-development and business development would have made a more immediate impact, according to Citi. \"We therefore feel that it may take time for the appointment to have an impact on the shares as we wait to see what actions the new CEO will take.\" Shares are down 0.6% at 78.59 euros. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 13, 2026 03:21 ET (08:21 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFXG1179.USD","symbol_name":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2611422131","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611422131","pubTimestamp":1770970860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0820 GMT - Sanofi's abrupt move to replace CEO Paul Hudson with Merck KGaA's head Belen Garijo only adds to near-term uncertainty for the French drugmaker, Citi analysts say in a research note. The company suffered several setbacks in clinical trials in the past year and needs to focus on a research-and-development turnaround, the analysts say. Garijo brings a long pharma career to the role, but a candidate from a major drugmaker with strong credentials in research-and-development and business development would have made a more immediate impact, according to Citi. \"We therefore feel that it may take time for the appointment to have an impact on the shares as we wait to see what actions the new CEO will take.\" Shares are down 0.6% at 78.59 euros. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4588":"碎股","SNY":"赛诺菲安万特","BK4007":"制药","SNYNF":"Sanofi","BK4585":"ETF&股票定投概念"},"translate_title":"赛诺菲首席执行官变动增加了近期的不确定性——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":0.9,"SNYNF":1.5},"content_text":"0820 GMT - Sanofi's abrupt move to replace CEO Paul Hudson with Merck KGaA's head Belen Garijo only adds to near-term uncertainty for the French drugmaker, Citi analysts say in a research note. The company suffered several setbacks in clinical trials in the past year and needs to focus on a research-and-development turnaround, the analysts say. Garijo brings a long pharma career to the role, but a candidate from a major drugmaker with strong credentials in research-and-development and business development would have made a more immediate impact, according to Citi. \"We therefore feel that it may take time for the appointment to have an impact on the shares as we wait to see what actions the new CEO will take.\" Shares are down 0.6% at 78.59 euros. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 13, 2026 03:21 ET (08:21 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}